Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,140.40
(
0.52%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
100.67
(
2.41%
)
Bitcoin
74,646.43
(
-0.26%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: TripleCutter post# 104059

Monday, 09/13/2010 2:55:29 PM

Monday, September 13, 2010 2:55:29 PM

Post# of 257253

MNTA/TEVA—What if there is no way to analytically characterize enox to FDA standard w out infringing on one [MNTA’s] patents? Teva could try to copy their science but would be infringing and couldn't get to market. Under this scenario, the FDA could approve other generics but they couldn't get to market due to the IP.

This is a problem Teva would be happy to have :- ) In the actual situation, Teva is presumably not using MNTA’s proprietary technology else their ANDA would have been approved by now.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now